Pfenex Inc. announced a change to the 2016 agreement under which they granted Jazz Pharmaceuticals worldwide rights to develop and commercialize multiple early stage hematology product candidates.   Under the amended agreement, Pfenex will now be eligible to receive an additional $43.5 million in amendment fee and development milestone payments as compared to the 2016 agreement, increasing the total value of the collaboration to an aggregate of $224.5 million.  Pfenex will also continue ...